Teva Settles Mississippi Allegations Of Price-Fixing Collusion In The Generic Drugs Market

Cozen O'Connor
Contact

Cozen O'Connor

  • Mississippi AG Lynn Finch reached a settlement with Teva Pharmaceuticals USA, Inc. (“Teva”) to resolve allegations of price fixing and market allocation for numerous generic drugs in violation of the Sherman Act.
  • The settlement stems from a 2019 complaint by 43 state AGs, and the Puerto Rico AG, against Teva and more than a dozen rivals, as well as related individual pharmaceutical executives, alleging that they colluded to divide the generic pharmaceutical customer base to artificially inflate prices in a coordinated manner for drugs used to treat numerous conditions, including multiple sclerosis, HIV, ADHD, kidney disease, and cancer, among other things.
  • Under the terms of the settlement, Teva will pay $925,000 to Mississippi for the voluntary dismissal of Mississippi’s claims in the 2019 case and other related cases.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Cozen O'Connor | Attorney Advertising

Written by:

Cozen O'Connor
Contact
more
less

Cozen O'Connor on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.